Exercise in Perimenopause to Improve Cognitive Health (EPIC)

April 13, 2026 updated by: Teresa Liu-Ambrose, University of British Columbia

Resistance Training and Cognitive Health in Perimenopause

Perimenopause is now considered a possible risk factor for dementia and may contribute to the fact that 2/3 of those living with Alzheimer's disease are females. Indeed, research studies show that middle-aged females demonstrate significant declines in their thinking abilities and detrimental changes in their brains as they go through perimenopause. Thus, perimenopausal females need strategies to bolster their brain health.

The World Health Organization strongly recommends physical activity interventions to reduce the risk of decline in thinking abilities. However, whether exercise can improve thinking abilities and brain health in perimenopausal females has not been examined. Our research aims to address this important knowledge gap in female brain health.

We will study the effects of a 6-month resistance exercise training (e.g., lifting free weights, exercise with weight machine) program on thinking abilities in 50 physically inactive perimenopausal females, aged 40 to 55 years, who are experiencing difficulties with their thinking abilities. In addition to measuring thinking abilities, we will determine if exercise benefits muscle health, heart health, sleep quality, psychological well-being, menopausal symptoms, and quality of life. We will also explore how resistance exercise training improves thinking abilities as such information can lead to new discoveries and therapies for brain health in females.

Study Overview

Detailed Description

  1. PURPOSE:

    To determine if progressive resistance training (PRT) can improve cognitive outcomes compared to balance, flexibility, and tone (BAT) exercises in perimenopausal females aged 40-55 years with subjective cognitive complaints.

  2. HYPOTHESIS:

    At the end of the intervention, PRT will result in an increase in words recalled during the RAVLT 20-minute delay vs no improve in BAT.

  3. JUSTIFICATION:

    The menopause transition (MT) negatively impacts cognitive function and the brain. The majority of perimenopausal females experiences cognitive difficulties and have subjective cognitive complaints (SCCs). Verbal episodic memory and processing speed are most negatively impacted by the MT. Cognitive and brain changes during the MT can significantly impact career and financial wellbeing. The MT is thus a critical window to intervene for female brain health. Exercise can reduce dementia risk factors and promote cognitive health. No published randomized controlled trials have examined the effect of exercise on cognitive outcomes in perimenopausal females.

  4. OBJECTIVE:

    To determine if 26 weeks of 2x/week progressive resistance training (PRT) can improve verbal episodic memory performance on the Rey Auditory Verbal Learning Test (RAVLT) compared with balance, flexibility, and tone exercises (BAT) for physically inactive perimenopausal females aged 40-55.

  5. RESEARCH DESIGN:

A 26-week, assessor-blinded, two-arm, proof-of-concept trial with 50 physically inactive perimenopausal females, aged 40 to 55 years, with subjective cognitive complaints. Participants will be randomized 1:1 to PRT or BAT and measured at baseline, 13 weeks, and 26 weeks.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1M9
        • Recruiting
        • University of British Columbia
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Are biological females, as assigned at birth
  • Are aged between 40 and 55 years
  • Had at least 1 menstrual period in the last 10 months
  • Are perimenopausal based on STRAW +10 Staging System, or answer "yes" to MQ6 questions of changes in periods, having hot flashes, or vaginal dryness, pain, or sexual concerns
  • Have an intact uterus
  • Have a Montreal Cognitive Assessment (MoCA) score >26/30, indicating normal cognition
  • Have subjective cognitive complaints defined as responding "yes" to "Do you feel like your memory or thinking is becoming worse?"
  • Completed high school education
  • Read and speak English with acceptable visual and auditory acuity
  • Are able to safely engage in moderate-intensity PRT as indicated by the PAR-Q+; and
  • Are able to provide informed consent.

Exclusion Criteria:

  • Are engaged in regular PRT (i.e., 2x/week) in the prior three months
  • Are diagnosed with cognitive impairment or dementia of any type
  • Are at high risk for cardiac complications during exercise
  • Have clinically important peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility
  • Are taking medications that negatively affect cognitive function, such as anticholinergics, major tranquilizers, and anticonvulsants
  • Have a BMI <15 or anorexia nervosa; g) had surgical menopause
  • Had endometrial ablation that resulted in the loss of menstruation
  • Have polycystic ovarian syndrome
  • Currently undergoing chemo
  • Are using estrogen-containing contraception in the last 12 months
  • Had premature ovarian failure; or
  • Are already enrolled in a drug or exercise trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Progressive Resistance Training (PRT)
Each PRT session will be 1-hr in duration and consists of a warm-up (10 mins), PRT (45 mins), and cool-down (5 mins). 2x/week and group-based.
The sessions will occur in the Exercise Prescription Suite of the Centre for Aging SMART at VCH; this suite is a fully-equipped gym that includes treadmills, bikes, pneumatic resistance training equipment, and free weights. The training stimulus will initially be at 3 sets of 10-15 repetitions with proper form. At week 4, training intensity will progress from 60-82% of predicted 1 repetition maximum (RM) using the 8RM method. Every 4 weeks the 8RM test will be repeated.
Other Names:
  • PRT
Active Comparator: Balance, Flexibility, and Tone Exercises (BAT)
Each BAT session will be 1-hr in duration. 2x/week and group-based.
Each BAT session will be 1-hr in duration and consist of Pilates mat exercises, Yoga-based poses and breathing, Kegel exercises, stretches, and relaxation techniques (e.g., visualization).
Other Names:
  • BAT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rey Auditory Verbal Learning Test (RAVLT)
Time Frame: Baseline, 13 weeks, 26 weeks
The RAVLT is a valid, reliable, and widely-used instrument of verbal episodic memory and learning, with normative values.
Baseline, 13 weeks, 26 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
NIH TB Cognitive Battery - Flanker Test
Time Frame: Baseline, 13 weeks, 26 weeks
A measure of executive functions
Baseline, 13 weeks, 26 weeks
NIH TB Cognitive Battery - Dimensional Change Card Sort Test
Time Frame: Baseline, 13 weeks, 26 weeks
A measure of executive functions
Baseline, 13 weeks, 26 weeks
NIH TB Cognitive Battery - Picture Sequence Memory Test
Time Frame: Baseline, 13 weeks, 26 weeks
A measure of visual episodic memory
Baseline, 13 weeks, 26 weeks
NIH TB Cognitive Battery - List Sorting Test
Time Frame: Baseline, 13 weeks, 26 weeks
A measure of working memory
Baseline, 13 weeks, 26 weeks
NIH TB Cognitive Battery - Pattern Comparison Processing Speed Test
Time Frame: Baseline, 13 weeks, 26 weeks
A measure of processing speed
Baseline, 13 weeks, 26 weeks
Everyday Memory Questionnaire
Time Frame: Baseline, 13 weeks, 26 weeks
A subjective measure of memory failure in everyday life
Baseline, 13 weeks, 26 weeks
Muscle strength of quads
Time Frame: Baseline, 13 weeks, 26 weeks
Muscle strength measure by isokinetic dynamometer
Baseline, 13 weeks, 26 weeks
Peripheral QCT of the tibia
Time Frame: Baseline, 13 weeks, 26 weeks
A measure of bone and muscle health
Baseline, 13 weeks, 26 weeks
Blood pressure
Time Frame: Baseline, 13 weeks, 26 weeks
Blood pressure - systolic and diastolic
Baseline, 13 weeks, 26 weeks
Lipid panel
Time Frame: Baseline, 26 weeks
Lipid levels
Baseline, 26 weeks
Hemoglobin A1-C
Time Frame: Baseline, 26 weeks
Average blood sugar levels
Baseline, 26 weeks
C-reactive protein
Time Frame: Baseline, 26 weeks
Measure of inflammation
Baseline, 26 weeks
Health resource utilization
Time Frame: Baseline, 13 weeks, 26 weeks
Cost of health resource used
Baseline, 13 weeks, 26 weeks
Carotid-femoral pulse wave velocity
Time Frame: Baseline, 13 weeks, 26 weeks
Arterial stiffness
Baseline, 13 weeks, 26 weeks
Pittsburgh Sleep Quality Index
Time Frame: Baseline, 13 weeks, 26 weeks
Subjective sleep quality
Baseline, 13 weeks, 26 weeks
Fatigue Severity Scale
Time Frame: Baseline, 13 weeks, 26 weeks
Subjective fatigue
Baseline, 13 weeks, 26 weeks
PHQ-9
Time Frame: Baseline, 13 weeks, 26 weeks
Depression severity
Baseline, 13 weeks, 26 weeks
GAD-7
Time Frame: Baseline, 13 weeks, 26 weeks
Generalized anxiety disorder
Baseline, 13 weeks, 26 weeks
Menopause Rating Scale
Time Frame: Baseline, 13 weeks, 26 weeks
Menopause symptoms
Baseline, 13 weeks, 26 weeks
EuroQol-5 Domain-5 Level
Time Frame: Baseline, 13 weeks, 26 weeks
Quality of life
Baseline, 13 weeks, 26 weeks
International Physical Activity Questionnaire
Time Frame: Every 30 days over 26 weeks
Physical activity
Every 30 days over 26 weeks
DEXA
Time Frame: Baseline, 13 weeks, 26 weeks
Lean mass
Baseline, 13 weeks, 26 weeks
DEXA
Time Frame: Baseline, 13 weeks, 26 weeks
Body fat
Baseline, 13 weeks, 26 weeks
Mediterranean-DASH Diet Intervention for Neurodegenerative Delay (MIND) Diet score
Time Frame: Baseline, 13 weeks, 26 weeks
Diet
Baseline, 13 weeks, 26 weeks
Productivity Questionnaire
Time Frame: Baseline, 13 weeks, 26 weeks
Measure of work productivity
Baseline, 13 weeks, 26 weeks
Brain-Derived Neurotrophic Factor
Time Frame: Baseline, 26 weeks
Neurotrophic Factor
Baseline, 26 weeks
IGF-1
Time Frame: Baseline, 26 weeks
Neurotrophic Factor
Baseline, 26 weeks
DEXA
Time Frame: Baseline, 13 weeks, 26 weeks
Appendicular Skeletal Muscle Mass Index (ASMI); a measure of sarcopenia
Baseline, 13 weeks, 26 weeks
Processing Speed by smartphone
Time Frame: Baseline, 13 weeks, 26 weeks
Processing Speed
Baseline, 13 weeks, 26 weeks
Memory by smartphone
Time Frame: Baseline, 13 weeks, 26 weeks
Memory
Baseline, 13 weeks, 26 weeks
Actigraph
Time Frame: Baseline, 13 weeks, 26 weeks
Using actigraphy data, quantify sleep quality (e.g., duration, efficiency, fragmentation).
Baseline, 13 weeks, 26 weeks
Actigraph
Time Frame: Baseline, 13 weeks, 26 weeks
Using actigraphy data, quantify physical activity (e.g., intensity and minutes)
Baseline, 13 weeks, 26 weeks
Actigraph
Time Frame: Baseline, 13 weeks, 26 weeks
Using actigraphy data, quantify sedentary behaviour (minutes)
Baseline, 13 weeks, 26 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Teresa Liu-Ambrose, PhD, University of British Columbia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 30, 2026

Primary Completion (Estimated)

December 15, 2026

Study Completion (Estimated)

January 30, 2027

Study Registration Dates

First Submitted

November 19, 2025

First Submitted That Met QC Criteria

November 26, 2025

First Posted (Actual)

December 9, 2025

Study Record Updates

Last Update Posted (Actual)

April 16, 2026

Last Update Submitted That Met QC Criteria

April 13, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • H25-01552

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Perimenopause

Clinical Trials on Progressive Resistance Training

Subscribe